149 related articles for article (PubMed ID: 37721443)
1. Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma.
Peng X; Shi Y; Zhang B; Xu C; Lang J
J Med Virol; 2023 Sep; 95(9):e29084. PubMed ID: 37721443
[TBL] [Abstract][Full Text] [Related]
2. A Novel Nucleic Acid Sensing-related Genes Signature for Predicting Immunotherapy Efficacy and Prognosis of Lung Adenocarcinoma.
Peng X; Wu H; Zhang B; Xu C; Lang J
Curr Cancer Drug Targets; 2024; 24(4):425-444. PubMed ID: 37592781
[TBL] [Abstract][Full Text] [Related]
3. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
Yu X; Chen P; Yi W; Ruan W; Xiong X
Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
[TBL] [Abstract][Full Text] [Related]
4. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
Front Immunol; 2022; 13():862527. PubMed ID: 35493471
[TBL] [Abstract][Full Text] [Related]
6. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study.
Lee YC; Wang JH; Chen CH; Hung CH; Lo KC; Yen YH; Kee KM; Hu TH; Lu SN; Kuo YH
Kaohsiung J Med Sci; 2021 Oct; 37(10):894-902. PubMed ID: 34166565
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
9. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
10. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
Zhao J; Luo Z; Fu R; Zhou J; Chen S; Wang J; Chen D; Xie X
Eur J Med Res; 2023 Dec; 28(1):571. PubMed ID: 38057871
[TBL] [Abstract][Full Text] [Related]
11. Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis.
Tang Y; Zhang Y; Hu X
Biomed Res Int; 2020; 2020():4251761. PubMed ID: 33376723
[TBL] [Abstract][Full Text] [Related]
12. The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma.
Cho SH; Pak K; Jeong DC; Han ME; Oh SO; Kim YH
J Cell Biochem; 2019 Mar; 120(3):4140-4146. PubMed ID: 30260026
[TBL] [Abstract][Full Text] [Related]
13. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
14. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
15. Differential association of STAT3 and HK-II expression in hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma.
Li M; Wang W; Jin R; Zhang T; Li N; Han Q; Wei P; Liu Z
J Med Virol; 2016 Sep; 88(9):1552-9. PubMed ID: 26889748
[TBL] [Abstract][Full Text] [Related]
16. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.
Yuan J; Liu Z; Wu Z; Yang J; Yang J
Int Immunopharmacol; 2022 Dec; 113(Pt A):109411. PubMed ID: 36461603
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of viral protein interaction networks in Hepatitis B virus and Hepatitis C virus infected HCC.
Yuan W; Huang T; Yu J; Zeng L; Lian B; He Q; Li Y; Zhang X; Zhou F; Xie L
Biochim Biophys Acta; 2014 Jan; 1844(1 Pt B):271-9. PubMed ID: 23774196
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
[TBL] [Abstract][Full Text] [Related]
19. A novel tumor immunotherapy-related signature for risk stratification, prognosis prediction, and immune status in hepatocellular carcinoma.
Sun J; Xi L; Zhang D; Gao F; Wang L; Yang G
Sci Rep; 2023 Oct; 13(1):18709. PubMed ID: 37907783
[TBL] [Abstract][Full Text] [Related]
20. Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma.
Shi Y; Huang G; Jiang F; Zhu J; Xu Q; Fang H; Lan S; Pan Z; Jian H; Li L; Zhang Y
Front Immunol; 2022; 13():1070593. PubMed ID: 36544763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]